


FAK-IN-20

| | |
|--------------------|---|
| Cat. No.: | HY-161358 |
| CAS No.: | 3004967-41-0 |
| Molecular Formula: | C ₂₇ H ₃₄ ClN ₇ O ₅ S |
| Molecular Weight: | 604.12 |
| Target: | FAK; Apoptosis |
| Pathway: | Protein Tyrosine Kinase/RTK; Apoptosis |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|-------------------------------------|---|
| Description | FAK-IN-20 (Compound 7b) is an inhibitor of FAK with an IC ₅₀ value of 0.27 nM. FAK-IN-20 exhibits anticancer activity. It can arrest the cell cycle in the G ₂ /M phase and induce cell apoptosis (apoptosis) by generating ROS ^[1] . |
| IC₅₀ & Target | IC ₅₀ : 0.27 nM (FAK) ^[1] . |
| In Vitro | <p>FAK-IN-20 (Compound 7b) (72 h) can inhibit cell proliferation in human tumor cell lines such as HCT116 (colon cancer), A549 (lung cancer), MDA-MB-231 (breast cancer), and HeLa (cervical cancer) with IC₅₀ values of 0.58, 0.75, 1.18, and 1.4 μM, respectively, demonstrating anticancer activity^[1].</p> <p>FAK-IN-20 (0.2-2 μM; 24 h) arrests the cell cycle in the G₂/M phase in HCT116 cells and (0.2-25 μM; 12 h) induces apoptosis by (1-125 μM; 12 h) triggering ROS production^[1].</p> <p>FAK-IN-20 (1 μM; 24 h) inhibits cell migration in HCT116 cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> |

REFERENCES

[1]. Li R, et al. Discovery of 2,4-diarylaminopyrimidine derivatives bearing sulfonamide moiety as novel FAK inhibitors. *Bioorg Chem.* 2024;144:107134.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA